Development of a new therapeutic drug candidate that suppresses only arrhythmias and protects cardiac function

A research group from Juntendo University and others revealed that 'Ryanozole', a novel compound selectively suppressing the type 2 ryanodine receptor, could be a promising treatment for catecholaminergic polymorphic ventricular tachycardia (CPVT). In mouse models, Ryanozole prevented and stopped arrhythmias without adverse effects on cardiac function seen with conventional drugs. Published in the British Journal of Pharmacology, it shows potential for clinical drug development.